Alzheimer's disease is a progressive neurodegenerative brain disorder that gradually destroys memory, thinking skills, and eventually the ability to perform daily tasks.
The global CNS biomarkers market is projected to reach USD 26.13 billion by 2035, amyloid beta therapeutics USD 26.50 billion, and calcineurin inhibitors USD 20.88 billion. AI integration is driving innovation across all three markets.
People with Down syndrome have a 90% to 95% lifetime risk of Alzheimer’s disease. Amyloid accumulation is almost inevitable by age 40, and baseline assessment is recommended by age 40 with annual follow-up.
A Neuron study reported that partial reprogramming of engram neurons with OSK restored memory in aged mice and improved learning and long-term memory in Alzheimer’s mouse models.
Support for non-animal testing is growing, but adoption remains slow. Great Britain recorded 2.64 million live animal uses in 2024, while the article cited regulatory barriers and high drug failure rates.
A large analysis of 131,821 health professionals found that two to three cups of caffeinated coffee a day were linked to a 19 percent lower dementia risk. One daily cup of caffeinated tea was linked to a 14 percent lower risk.
Two studies of older adults with type 2 diabetes linked diabetic retinal disease with higher dementia risk. DME and more severe diabetic retinopathy were associated with higher all-cause and vascular dementia risk, but not consistently with Alzheimer’s disease.
AbbVie raised 2026 revenue and EPS guidance after first-quarter results beat estimates, with Skyrizi and Rinvoq driving growth. Humira erosion continued as neuroscience, oncology and pipeline assets supported the outlook.
A Johns Hopkins study found GLP-1 users face increased dementia risk after a decade, possibly due to longer lifespan. A separate JCI review found GLP-1 drugs show neuroprotective signals in preclinical studies but consistent cognitive benefits in humans remain unproven.
A study of 2,282 adults aged 60 and older found anemia was associated with higher Alzheimer’s disease blood biomarkers and a 66% higher chance of developing dementia. The highest risk was seen in participants with both anemia and higher biomarker levels.
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07599670 |
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenous ABBV-1758 Moves Through the Body of Adult Participants With Alzheimer's Disease |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07579689 |
Effects of Ginkgo Biloba on Blood Biomarkers in Mild Cognitive Impairment |
NOT_YET_RECRUITING | PHASE4 |
| NCT07573046 |
Validation Study of the ExéSem Battery Designed to Differentiate the Contribution of Executive Functions in Semantic Disorders |
NOT_YET_RECRUITING | |
| NCT07553338 |
Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease |
RECRUITING | PHASE2 |
| NCT07485153 |
A Study to Compare Two Different Sleep Tests in Participants With No Symptoms or Early Symptoms of Alzheimer's Disease |
NOT_YET_RECRUITING | |
| NCT07479914 |
Art of Memory for Cognitive Enhancement in the Monza Brain Health Service |
ACTIVE_NOT_RECRUITING | NA |
| NCT07457138 |
Lombard Cohort of Brain Health Services |
RECRUITING | |
| NCT07391436 |
Use of Wearables for Identifying Factors Associated With Mild Cognitive Impairment and Early-Stage Alzheimer's Disease |
NOT_YET_RECRUITING | |
| NCT07346794 |
The Underlying Neural Mechanism of TMS in Improving the Imbalance of "Microbiota-brain-gut Axis" in Alzheimer 's Disease Population |
NOT_YET_RECRUITING | NA |
| NCT07328386 |
Effect of Cervical Lymphaticovenous and Lymph Node-to-Vein Anastomosis in Patients With Intracranial Lymphatic Circulation Disorder |
RECRUITING | NA |
